PulseAugur
EN
LIVE 09:05:49

OncoTraj benchmark launched for lung cancer drug resistance prediction

By PulseAugur Editorial · [2 sources] ·

Researchers have introduced OncoTraj, a new public benchmark dataset designed to advance the prediction of drug resistance in EGFR-mutant non-small-cell lung cancer. The dataset comprises longitudinal patient trajectories from 813 individuals treated with osimertinib, harmonized from three clinical-genomic sources. OncoTraj includes three defined tasks for model evaluation: predicting progression at 12 months, estimating time to progression, and classifying resistance mechanisms. Initial evaluations with various baseline models, including transformers, indicate that current single-timepoint snapshot features limit predictive accuracy, suggesting a need for serial ctDNA data in future iterations. AI

IMPACT Establishes a standardized benchmark for AI models in predicting cancer drug resistance, potentially accelerating clinical applications.

RANK_REASON The cluster contains a research paper introducing a new benchmark dataset and evaluation tasks.

Read on arXiv cs.LG →

AI-generated summary · Google Gemini · from 2 sources. How we write summaries →

COVERAGE [2]

  1. arXiv cs.LG TIER_1 English(EN) · Abhijoy Sarkar, Aarchi Singh Thakur ·

    OncoTraj: a public benchmark for longitudinal resistance prediction in EGFR-mutant non-small-cell lung cancer on osimertinib

    arXiv:2606.11144v1 Announce Type: new Abstract: Resistance to first-line osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) is the canonical example of predictable clonal evolution under therapeutic pressure, yet no public benchmark exists for training or evaluating co…

  2. arXiv cs.LG TIER_1 English(EN) · Aarchi Singh Thakur ·

    OncoTraj: a public benchmark for longitudinal resistance prediction in EGFR-mutant non-small-cell lung cancer on osimertinib

    Resistance to first-line osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) is the canonical example of predictable clonal evolution under therapeutic pressure, yet no public benchmark exists for training or evaluating computational models on the corresponding longitud…

RELATED TOPICS